U.S. Bioscience’s Ethyol
Executive Summary
Firm submits amendments to its NDA for the chemoprotective drug to FDA, U.S. Bioscience reports Aug. 31. Included in the amendment are results from a trial of 200 patients with advanced ovarian cancer treated with cyclophosphamide and cisplatin, and other additional clinical and preclinical data, the west Conshohocken, Penn.-based company notes. U.S. Bioscience had halted the ovarian cancer patient trial after data on 121 of the 200 proposed patients had been collected and submitted an NDA based on the trial; however, FDA's Oncologic Drugs Advisory Committee recommended in January that the trial be completed.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth